Results 101 to 110 of about 50,260 (281)
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
Journal of the European Academy of Dermatology and Venereology, EarlyView.In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat +22 more
wiley +1 more source
Geophysical Monograph Series, Page i-xiv., 2020 This book is Open Access. A digital copy can be downloaded for free from Wiley Online Library.
Explores the behavior of carbon in minerals, melts, and fluids under extreme conditions
Carbon trapped in diamonds and carbonate-bearing rocks in subduction zones are examples of the continuing exchange of substantial carbon ...
wiley +1 more source
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study
Journal of the European Academy of Dermatology and Venereology, EarlyView.Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth +8 more
wiley +1 more source
, 1985 One Hundred and Fifty Years Ago. The Great Fire on Isabela. Campaign for a CDF Endowment Fund. The Extraordinary Consequences of the Extraordinary El Niño.
core
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes +7 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.This analysis used a large clinical trial data set (>30,000 patient visits across >2800 patients) and novel statistical methodologies (including frequency cross‐over analysis and means based on spline regression) to develop severity threshold bands for clinician‐ and patient‐reported outcome measures for adults with moderate‐to‐severe atopic dermatitis.
Andreas Wollenberg +7 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster +68 more
wiley +1 more source
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
Journal of the European Academy of Dermatology and Venereology, EarlyView.The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos +15 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel +69 more
wiley +1 more source
Journal of Fish Biology, EarlyView.Abstract The smooth hammerhead (Sphyrna zygaena) is typically considered an oceanic species and is only rarely observed in the cooler coastal waters of the northeastern Atlantic. On 20 December 2024, a juvenile S. zyganea was captured at 25 m depth in the inner Ría de Pontevedra (Rías Baixas, northwest Spain).
Xabier Pin +3 more
wiley +1 more source